Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 11:01AM ET
117.12
Dollar change
+0.29
Percentage change
0.25
%
Index- P/E1761.20 EPS (ttm)0.07 Insider Own6.06% Shs Outstand93.73M Perf Week-3.51%
Market Cap11.07B Forward P/E10.98 EPS next Y10.67 Insider Trans-0.48% Shs Float88.80M Perf Month-10.85%
Income16.90M PEG- EPS next Q-0.12 Inst Own87.22% Short Float7.31% Perf Quarter-5.59%
Sales1.40B P/S7.89 EPS this Y160.96% Inst Trans6.35% Short Ratio4.98 Perf Half Y25.95%
Book/sh10.17 P/B11.51 EPS next Y201.68% ROA0.54% Short Interest6.49M Perf Year-10.21%
Cash/sh14.71 P/C7.96 EPS next 5Y- ROE2.02% 52W Range55.25 - 146.68 Perf YTD21.46%
Dividend Est.- P/FCF- EPS past 5Y-1.21% ROI0.76% 52W High-20.15% Beta0.84
Dividend TTM- Quick Ratio3.44 Sales past 5Y32.89% Gross Margin85.20% 52W Low111.98% ATR (14)5.07
Dividend Ex-Date- Current Ratio4.05 EPS Y/Y TTM101.12% Oper. Margin-6.76% RSI (14)41.70 Volatility3.86% 4.10%
Employees1314 Debt/Eq1.44 Sales Y/Y TTM43.83% Profit Margin1.20% Recom1.40 Target Price165.90
Option/ShortYes / Yes LT Debt/Eq1.33 EPS Q/Q106.22% Payout- Rel Volume0.54 Prev Close116.83
Sales Surprise8.94% EPS Surprise2768.22% Sales Q/Q63.10% EarningsMay 01 AMC Avg Volume1.30M Price117.12
SMA20-4.62% SMA50-6.49% SMA2002.14% Trades Volume190,172 Change0.25%
Date Action Analyst Rating Change Price Target Change
May-31-24Initiated Piper Sandler Overweight $157
May-28-24Downgrade RBC Capital Mkts Outperform → Sector Perform $157 → $142
May-14-24Upgrade Oppenheimer Perform → Outperform $180
Jan-31-24Initiated BMO Capital Markets Outperform $170
Dec-13-23Resumed Citigroup Buy $113
Dec-12-23Initiated Deutsche Bank Buy $109
Nov-21-23Initiated Wedbush Outperform $224
Oct-31-23Downgrade Oppenheimer Outperform → Perform
Oct-31-23Downgrade Cantor Fitzgerald Overweight → Neutral $166 → $40
Jun-23-23Downgrade Evercore ISI Outperform → In-line $139
Jun-13-24 04:04PM
01:07PM
07:00AM
Jun-06-24 07:00AM
May-31-24 05:45PM
11:31AM Loading…
11:31AM
May-29-24 05:48PM
08:28AM
May-28-24 10:52PM
May-24-24 11:57AM
May-23-24 07:10AM
May-17-24 08:05AM
May-14-24 07:30AM
May-04-24 12:00PM
May-03-24 10:07AM
03:42PM Loading…
May-02-24 03:42PM
11:30AM
11:13AM
11:08AM
07:52AM
06:01AM
03:32AM
May-01-24 08:55PM
07:30PM
07:30PM
05:20PM
05:06PM
04:19PM
04:05PM
09:15AM
06:38PM Loading…
Apr-30-24 06:38PM
09:28AM
Apr-29-24 03:20PM
Apr-24-24 08:30AM
Apr-13-24 09:39PM
Apr-08-24 04:13PM
Apr-06-24 08:45AM
Apr-02-24 07:04AM
Mar-29-24 04:00PM
11:30AM
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Feb-28-24 06:00PM
04:23PM
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murray DallanChief Customer OfficerMay 02 '24Sale140.003,635508,90018,125May 06 08:09 PM
Boor Kathryn JeanDirectorMar 11 '24Sale122.9376193,5507,516Mar 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Option Exercise13.9015,000208,50037,840Mar 11 08:02 PM
Wigzell Hans Lennart RudolfDirectorMar 08 '24Sale123.2515,0001,848,79522,840Mar 11 08:02 PM
Mayo StephenDirectorMar 05 '24Sale122.963,135385,4806,621Mar 06 08:00 PM
Arif BilalChief Tech Ops OfficerMar 01 '24Sale128.842,000257,67626,836Mar 05 08:00 PM
Brown Ryan EdwardEVP, General CounselMar 01 '24Sale125.342,000250,68031,827Mar 05 08:00 PM
Estepan Ian MichaelChief Financial OfficerMar 01 '24Sale128.301,200153,96039,114Mar 05 08:00 PM
BEHRENS M KATHLEENDirectorNov 03 '23Option Exercise29.0315,000435,450174,993Nov 06 08:00 AM
Barry RichardDirectorNov 03 '23Buy78.8150,0003,940,500140,000Nov 06 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 03 '23Buy79.3625,2252,001,800390,307Nov 06 08:00 AM
Chambers Michael AndrewDirectorAug 14 '23Buy109.479,9791,092,429246,996Aug 15 08:00 AM
Chambers Michael AndrewDirectorAug 11 '23Buy108.0523,6862,559,272237,017Aug 14 08:00 AM
Chambers Michael AndrewDirectorAug 10 '23Buy106.1534,8673,701,067213,331Aug 11 07:40 AM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Option Exercise29.0315,000435,45035,994Aug 08 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 04 '23Sale106.7215,0001,600,80020,994Aug 08 08:00 PM